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To explain the very high frequency of cystic fibrosis (CF) mutations in most populations of European descent, it
has been proposed that CF heterozygotes have a survival advantage when infected withVibrio cholerae orEscherich-
ia coli, the toxins of which induce diarrhea by stimulation of active intestinal chloride secretion. Two assumptions
underlie this hypothesis: (1) chloride conductance by the CF transmembrane conductance regulator (CFTR) is the
rate-limiting step for active intestinal chloride secretion at all levels of expression, from approximately zero in
patients with CF to normal levels in people who are not carriers of a mutation; and (2) heterozygotes have smaller
amounts of functional intestinal CFTR than do people who are not carriers, and heterozygotes therefore secrete
less chloride when exposed to secretagogues. The authors used an intestinal perfusion technique to measure in vivo
basal and prostaglandin-stimulated jejunal chloride secretion in normal subjects, CF heterozygotes, and patients
with CF. Patients with CF had essentially no active chloride secretion in the basal state, and secretion was not
stimulated by a prostaglandin analogue. However, CF heterozygotes secreted chloride at the same rate as did people
without a CF mutation. If heterozygotes are assumed to have less-than-normal intestinal CFTR function, these
results mean that CFTR expression is not rate limiting for active chloride secretion in heterozygotes. The results
do not support the theory that the very high frequency of CF mutations is due to a survival advantage that is
conferred on heterozygotes who contract diarrheal illnesses mediated by intestinal hypersecretion of chloride.
Introduction
It is generally agreed that cystic fibrosis (CF) (MIM
219700) is the most common fatal autosomal recessive
genetic defect in white persons of European descent (Ro-
meo et al. 1989; Morral et al. 1994; Knowles et al.
1999). Approximately 1 in 3,000 white babies is born
with the disease, and ∼1 in 28 healthy white adults is a
carrier of a CF gene mutation. There is no evidence that
this high frequency is the result of either random genetic
drift or a propensity for new mutations (Rodman and
Zamudio 1991; Bertranpetit and Calafell 1996). It has
therefore been suggested that the high frequency of gene
mutations in the white population is due to a selective
advantage of being a heterozygote. There are at least
two general ways in which such an advantage could be
conferred. The first is increased fertility of heterozygotes,
which apparently is not the case (Jorde and Lathrop
1988). The second is protection of heterozygotes against
another disease.
Received August 29, 2000; accepted for publication September 21,
2000; electronically published October 30, 2000.
Address for correspondence and reprints: Dr. John S. Fordtran, Bay-
lor University Medical Center, 2nd Floor HOB, 3500 Gaston Avenue,
Dallas, TX 75246.
 2000 by The American Society of Human Genetics. All rights reserved.
0002-9297/2000/6706-0008$02.00
With the discoveries that (1) CF is due to a defect in
a gene product—the CF transmembrane conductance
regulator (CFTR) (MIM 602421)—that normally me-
diates chloride permeability in epithelial cells and (2)
CFTR mediates secretory diarrhea due to the toxins of
Vibrio cholerae and Escherichia coli, it was logical to
propose that the high frequency of CF mutations in the
white population may be due to protection of hetero-
zygotes from dehydration due to diarrheal diseases
(Quinton 1982; Baxter et al. 1988; Kopelman 1993;
Grubb and Gabriel 1997; Knowles et al. 1999). The
fundamental assumptions underlying this heterozygote-
selective-advantage hypothesis are as follows (modified
from Gabriel et al. 1994): (1) chloride conductance by
CFTR is the rate-limiting step for active intestinal chlo-
ride secretion at all levels of functional CFTR expres-
sion, from approximately zero in patients with CF to
normal levels in people who are not carriers of a mu-
tation; (2) heterozygotes have fewer (presumably 50%)
functional intestinal CFTR chloride channels than do
people who are not carriers, and they therefore secrete
less chloride when exposed to secretagogues.
This theory is supported by two lines of evidence.
First, the intestine of patients with CF (homozygotes for
CFTR mutations) does not actively secrete chloride in
response to a variety of secretagogues (Berschneider et
al. 1988; Baxter et al. 1989; O’Loughlin et al. 1991;
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Chao et al. 1994). Second, in one study, mice that were
heterozygous for CF were shown to have one half the
normal amount of CFTR protein and one half the nor-
mal intestinal fluid secretion after exposure to cholera
toxin (Gabriel et al. 1994).
There are two arguments against the heterozygote-
selective-advantage theory. First, another study of a het-
erozygous mouse model did not find a defect in intes-
tinal secretion in response to several secretagogues,
including cholera toxin (Cuthbert et al. 1995). It has
been suggested that this may have resulted from amilder
intestinal phenotype that could have masked the dif-
ference between the responses of heterozygotic and nor-
mal mice (Grubb and Gabriel 1997). Second, CF mu-
tations are not common in areas of the world where
infectious diarrhea is most common and most lethal
(Fontelo 1995). To reconcile this discrepancy, some re-
searchers have suggested that, in certain regions of the
world, there may be a disadvantage of being a hetero-
zygote that outweighs the survival advantage from
diarrhea; for example, increased salt lost in sweat in
tropical climates by heterozygotes would cost more lives
than would be saved when heterozygotes were exposed
to diarrheal diseases (Rodman and Zamudio 1991;
Quinton 1994).
Although this heterozygote-selective-advantage the-
ory is highly appealing and is often invoked, no studies
have been conducted in humans to determine whether
heterozygotes have a subnormal rate of active intestinal
chloride secretion. The purpose of our research was
therefore to measure intestinal chloride secretion in nor-
mal subjects, parents of children with CF (i.e., hetero-
zygotes for CF mutations), and patients with CF. Our
experiment was conducted under in vivo conditions, in
the jejunum. A prostaglandin analogue was used as a
chloride secretagogue (Gaginella 1990; Chang and Rao
1991). For experimental use in humans, prostaglandins
are advantageous because their effect on the intestine
disappears soon after the agent is withdrawn, whereas
the intestine continues to secrete for several days after
transient exposure to cholera toxin, an effect that some-
times requires hospitalization of subjects (Schiller et al.
1997).
Subjects and Methods
This research was approved by the Institutional Review
Board for Human Protection of Baylor University Med-
ical Center. Informed consent was obtained, and the sub-
jects were paid a fee for their participation.
Blood leukocytes or buccal cells were assayed for 86
CFTRmutations (Genzyme Genetics), which account for
∼90% of the mutations that cause CF. Because a CF
mutation on one chromosome and a 5T allele on intron
8 of the CFTR gene on the other chromosome cause low
CFTR expression and atypical forms of CF (Chillon et
al. 1995), the poly(T) variant on intron 8 of the CFTR
gene was also measured (Genzyme Genetics).
Jejunal secretion was measured by a constant-per-
fusion technique (Davis et al. 1980), using a triple-lu-
men tube and a nonabsorbable marker. The infusion
site of the tube was located at the ligament of Treitz;
the mixing segment was 10 cm long, and the test seg-
ment was 30 cm. The standard perfused solution con-
tained the following: 140 mMNa, 4 mM K, 104 mM
Cl, 0 mM HCO3
, and 20 mM SO4
2. Mannitol 40
mMwas added to make the solution isotonic to plasma,
and 2 g polyethylene glycol/liter was the nonabsorbable
marker. During perfusion of this bicarbonate-free so-
lution, active absorptive mechanisms by the jejunum are
eliminated, and the true rate of active chloride secretion
is revealed (Davis et al. 1980). The test solution was
infused at a rate of 10 ml/min. Perfusion periods con-
sisted of 50 min of equilibration and 60-min study
periods, during which samples were collected for anal-
ysis by methods published elsewhere (Davis et al. 1980).
The rate of absorption or secretion by the 30-cm
segment of jejunum located between the proximal and
distal aspiration sites was calculated using standard
equations. Potential difference (PD) was measured con-
tinuously between a flowing intraluminal electrode and
a subcutaneous reference electrode (Read and Fordtran
1979).
There were two study periods for each subject, the
first to measure basal active chloride secretion and the
second to measure the rate of active chloride secretion
under stimulation by a prostaglandin analogue. For the
latter purpose, we used a prostaglandin E1 agonist
(misoprostol; G. D. Searle), in a concentration of 800
mg/liter. The amount of misoprostol infused during the
110-min perfusion was 880 mg. By comparison, the dose
of misoprostol used clinically for prevention of gastro-
duodenal ulcers induced by nonsteroidal anti-inflam-
matory drugs is 100–200 mg orally four times per day.
Statistical significance of differences was assessed us-
ing a two-way analysis of variance on the ranks (because
the data were not normally distributed), and all pairwise
multiple comparisons were assessed by the Tukey test.
P values !.05 were considered statistically significant.
Results
The distribution of age, ethnicity, and sex in the group
of normal subjects was similar to that in the group of
parents of patients with CF. None of the normal subjects
had a CFTR mutation. All parents of patients with CF
had a mutation on one of their CFTR alleles (table 1).
None of the normal subjects or parents had a 5T allele
on the CFTR intron 8. Seven of the eight patients with
CF were found to have mutations on both alleles. The
remaining patient (patient 6) had only one detected
CFTR mutation; however, because this patient definitely
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Table 1
Demographics and CFTR Mutation Analysis
Group and
Subject (Sex [Age])a Ethnicityb
CFTR Mutation
Analysisc
CFTR Intron 8
Poly(T) Analysis
Parents:
1 (M [28]) White Negative/DF508 7T/9T
2 (F [32]) White Negative/DF508 7T/9T
3 (F [44]) White Negative/DF508 7T/9T
4 (M [36]) AA Negative/DF508 9T/9T
5 (M [54]) White Negative/N1303K 7T/9T
6 (F [24]) White Negative/S549R 7T/7T
7 (F [30]) AA Negative/31201G-A 7T/7T
Patients:
1 (F [20]) White DF508/N1303K 9T/9T
2 (F [22]) White DF508/DF508 9T/9T
3 (F [33]) White DF508/18981G-A 7T/9T
4 (F [27]) White DF508/DI507 7T/9T
5 (M [28]) White DF508/DF508 9T/9T
6 (F [31]) White Negative/DF508 7T/9T
7 (M [18]) White DF508/M1101K 7T/9T
8 (M [18]) White DF508/M1101K 7T/9T
a Members of the patient group had CF; members of the parent group had
offspring with CF who were not necessarily included in the present study.
b AA p African American.
c Negative p alleles testing negative for the 86 most-common CFTR
mutations.
has CF (lung disease and positive sweat test), we believe
that she has a second mutation that was missed by the
genetic analysis that was performed. All eight patients
have chronic recurrent sinopulmonary infections, and all
but one (patient 6) have steatorrhea due to pancreatic
insufficiency. Three of the patients (patients 5, 7, and 8)
had a meconium ileus as newborns, two (patients 7 and
8) had distal intestinal obstruction syndrome at ages 7
and 10 years, and another (patient 3) has hepatobiliary
disease, presumably due to CF.
As shown in table 2 and figure 1, normal subjects in
the basal state secreted chloride at a rate of 5.6 mEq/
h/30 cm. The concentrations of chloride in fluid col-
lected at the proximal and distal ends of the 30-cm test
segment were higher than the chloride concentration in
the infused solution and were also higher than the chlo-
ride concentration in serum. The PDwas 1.5 mV (lumen
negative). Therefore, chloride was secreted against both
a concentration gradient and an electric gradient, es-
tablishing the active nature of chloride secretion. In con-
trast, sodium secretion can be explained by passive dif-
fusion. Water was secreted at a rate of 36 ml/h/30 cm.
During intraintestinal infusion of the prostaglandin an-
alogue, the chloride secretion rate increased to 16.4
mEq/h/30 cm, and this was associated with an increase
in lumen-negative PD. The increased active secretion of
chloride was followed by increased passive secretion of
sodium and water to maintain electric and osmolar bal-
ance (table 2).
Basal and prostaglandin-stimulated levels of active
chloride secretion in the heterozygotes were similar to
those in normal subjects. Moreover, prostaglandin in-
fusion in the heterozygotes was associated with a PD
increase similar to that noted in the normal subjects.
Four of the seven heterozygotes had a DF508 mutation,
and three had other mutations. Basal and prosta-
glandin-stimulated secretion rates and PD were similar
in these two subgroups.
Chloride secretion in the patients with CF was ap-
proximately zero during the basal as well as during the
prostaglandin-infusion period. Moreover, in contrast to
normal subjects and to heterozygotes, in whom PD was
always lumen negative, the average PD in patients with
CF was approximately zero under basal conditions and
did not move in a negative direction when the prosta-
glandin analogue was administered.
Discussion
Our finding that patients with CF (homozygotes) have
essentially no active chloride secretion in response to a
secretagogue is in agreement with previous observations
(Berschneider et al. 1988; Baxter et al. 1989; O’Loughlin
et al. 1991; Chao et al. 1994) and indicates that a very
low level of expression of functional intestinal CFTR
protein precludes stimulation of active chloride secre-
tion. However, we found that CFTR heterozygotes have
normal rates of basal and stimulated active chloride se-
cretion. If it is assumed that heterozygotes have less-
than-normal intestinal CFTR function, our results mean
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Figure 1 Basal and prostaglandin-stimulated chloride secretion
and PD in normal control subjects ( ), in heterozygous CFTRnp 7
mutation carriers ( ), and in patients with CF ( ).np 7 np 8
Table 2
Basal and Prostaglandin-Stimulated Chloride, Sodium, and Water Secretion in Subjects With and Without CFTR Mutations
SUBJECTS AND PERIODS
[Cl] LEVELS IN mEq/liter SECRETION OF
PD
(mV)bSerum
Proximal
End
Distal
End
Cl
(mEq/h/30 cm)
Na
(mEq/h/30 cm)
H2O
(ml/h/30 cm)a
Normal (np7):
Basal 104.6  .9 106.4  .4 109.1  .6 5.6  1.3 5.5  1.2 36.0  10.1 1.5  .4
Prostaglandin … 109.9  .8 114.5  1.1 16.4  2.7 17.2  2.7 116.6  19.4 5.5  1.2
Heterozygous CFTR mutation
carriers (np7):
Basal 106.6  1.0 108.1  1.3 111.6  1.7 5.2  1.5 5.0  1.7 26.7  10.2 2.6  .5
Prostaglandin … 112.4  1.6 116.7  2.0 18.3  4.3 19.5  4.5 127.6  28.3 6.5  1.4
Patients with CF (np8):
Basal 105.8  .9 103.6  1.2 106.2  1.1 1.5  .9 .4  1.4 1.1  8.2 .2  .5
Prostaglandin … 103.4  1.0 103.9  1.4 2.1  .8 2.7  .7 17.1  4.6 1.2  1.0
NOTE.— Data are mean SE. None of the differences between normal and heterozygous subjects were statistically significant. All differences
in secretion rates and PD of normal subjects vs. CF patients were statistically significant ( ).P ! .05
a Minus sign denotes absorption rather than secretion.
b Minus sign indicates lumen-negative PD, plus sign denotes lumen-positive PD.
that CFTR expression is not rate limiting for active chlo-
ride secretion in human heterozygotes. The rate-limiting
step at the heterozygote level of CFTR expression could
be one of three factors: (1) the degree to which intra-
cellular cyclic nucleotides are increased by a secreta-
gogue; (2) the response of transporters on the basolateral
membrane of epithelial cells, which are involved in es-
tablishing the electrochemical gradients that cause chlo-
ride to exit epithelial cells through the CFTR channels
(Field and Semrad 1993); or (3) the release of neuro-
transmitters that are apparently essential for secreta-
gogue action (Lundgren et al. 1989; Castagliuolo et al.
1994).
The degree to which these findings refute the hy-
pothesis that heterozygotes have a survival advantage
if they contract diarrhea caused by the toxins of V. chol-
erae or E. coli depends on three main considerations.
First, did we study an appropriate group of hetero-
zygotes? The most common mutation in the white pop-
ulation is DF508, which accounts for ∼66% of all mu-
tations (Knowles et al. 1999). Moreover, DF508 is
considered to be a very old mutation (Morral et al.
1994). If the survival-advantage theory is correct,
DF508 is therefore the most likely mutation that would
confer reduced intestinal secretory capacity to hetero-
zygotes (Cuthbert et al. 1995). Four of the heterozygotes
studied in the present study had the DF508 mutation.
Furthermore, all of the CFTR mutations in the heter-
ozygotes in our experiment are known, when present
on both alleles, to cause severe forms of CF, with a
nearly complete absence of chloride conductance in ep-
ithelial tissues (The Cystic Fibrosis Genotype-Phenotype
Consortium 1993; Bienvenu et al. 1996; Romey et al.
1999). We therefore believe that we studied an appro-
priate group of heterozygotes.
Second, does prostaglandin-induced active chloride
secretion reflect secretion induced by the toxins of V.
cholerae and E. coli? Toxin- and prostaglandin-induced
intestinal secretion have the same profile of inhibition
by neuropharmacological agents (Lundgren et al. 1989;
Castagliuolo 1994). Both prostaglandin and toxins in-
crease intracellular cAMP, which causes activation of
CFTR channels (Field and Semrad 1993). Thus, CFTR
channels are the final common pathway for chloride
secretion for both toxins and prostaglandin. Because
the CFTR defect in patients with CF is distal to the
neuropharmacological and intracellular events that oc-
cur in response to various secretagogues (Hitchin et al.
1991), we believe that prostaglandin-induced secretion
provides a good measurement of CFTR activity and that
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results obtained with prostaglandin would yield the
same conclusions as do studies with toxins, provided
that similar rates of chloride secretion were obtained.
Petritsch and coworkers carried out a dose-response
study of cholera toxin–induced chloride secretion in the
jejunum of normal subjects, using methods similar to
those of the present study. These workers found a max-
imum chloride secretion of 14.6 mEq/h/30 cm, with the
largest dose of toxin tested (Petritsch et al. 1992). The
prostaglandin dose that we used resulted in a chloride
secretion rate of 16.4 mEq/h/30 cm. Furthermore, dur-
ing administration of the prostaglandin analogue to
normal subjects in our study, chloride secretion rates
were somewhat higher than those observed in the je-
junum of actual patients with acute cholera, as mea-
sured by a similar perfusion technique (Banwell et al.
1970). This indicates that the dose of prostaglandin
analogue employed in our experiment elicited a rate of
secretion that is clinically relevant to severe diarrheal
diseases.
Third, our studies were conducted in the jejunum but
not in the ileum or the colon. We do not believe that
this limits the conclusions that can be reached from our
study, because toxins of both V. cholerae and E. coli
cause diarrhea mainly by inducing fluid secretion in the
proximal small intestine (Banwell et al. 1970; Hamer
and Gorbach 1998).
We have no good explanation for the discrepancy
between our results and the study by Gabriel et al.
(1994), which showed that their mouse heterozygotes
had approximately one half the normal intestinal se-
cretion rate when exposed to cholera toxin. However,
Cuthbert et al. (1995) found perfectly normal responses
to cholera toxin (as well as to a variety of other secre-
tagogues) in a different heterozygote mouse model. It
is possible that the Cuthbert mouse model is more rel-
evant to human heterozygotes than is the Gabriel mouse
model. However, as Cuthbert et al. observed, all mouse
heterozygotes have null mutations and therefore have
only one allele capable of the generation of CFTR pro-
teins. This is unlike the situation in human hetero-
zygotes, where one allele can produce an altered CFTR
protein that may have some functional capability. Ul-
timately, it would appear that only a study of human
heterozygotes can prove or disprove the two major as-
sumptions of the theory.
Our results provide evidence against the theory that
CF heterozygotes have a survival advantage when they
contract diarrhea mediated by stimulation of active in-
testinal chloride secretion. Our results are obviously not
applicable to protection of CF heterozygotes against
other pathogenetic factors involved in the production
of diarrhea.
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